Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

New insights on the treatment and prognosis of male breast cancer

A recent analysis reveals that treatment of male breast cancer has evolved over the years. In addition, certain patient-, tumour-, and treatment-related factors are linked with better survival.

The findings have been published in the journal CANCERa peer-reviewed journal of the American Cancer Society.

Male breast cancer (MBC) comprises one percent of all breast cancer cases, yet no prospective randomised clinical trials specifically focused on MBC have been successfully completed.

Some studies suggest that the incidence of MBC may be rising, however, and there is an increasing appreciation that the tumour biology of MBC differs from that of female breast cancer.

To examine how MBC has been treated in the United States in recent years, and to identify factors associated with patient prognosis, a team led by Kathryn Ruddy, MD, MPH, and Siddhartha Yadav, MBBS, at Mayo Clinic in Rochester, analysed information from the National Cancer Database on men diagnosed with stage I-III breast cancer between 2004 and 2014.

A total of 10,873 patients with MBC were included, with a median age at diagnosis of 64 years.

Breast-conserving surgery was performed in 24 percent of patients, and 70 percent of patients undergoing breast conservation received radiation.

44 percent of patients received chemotherapy, and 62 percent of patients whose tumours expressed the oestrogen receptor received anti-oestrogen therapy.

During the study period, there was a significant increase in the rates of total mastectomy, contralateral prophylactic mastectomy, and post-breast conservation radiation, as well as an increase in the rate of genomic testing on tumours and the use of anti-oestrogen therapy.

Tamoxifen is the standard anti-oestrogen medication recommended for treatment of hormonally sensitive MBC, but this study was not able to assess specific medications used.

Factors associated with worse overall survival were older age, black race, multiple co-morbidities, high tumour grade and stage, and undergoing total mastectomy.

Residing in higher income areas; having tumours that express the progesterone receptor; and receiving chemotherapy, radiation, and anti-oestrogen therapy were associated with better overall survival.

"Our study highlights unique practice patterns and factors associated with prognosis in MBC, furthering our understanding of the treatment and prognosis of MBC," said Dr Ruddy. "The racial, economic, and age-related health disparities we found could inform future efforts to target interventions to optimise outcomes in men with breast cancer."

Source: Wiley

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation